Last updated: October 26, 2026
REGRANEX, the branded becaplermin 0.01% topical gel, occupies a narrow market in diabetic foot-ulcer treatment. FDA approval dates to 1997, but commercial performance has been constrained by a boxed warning concerning malignancy risk, limited treatment duration, high acquisition cost, reimbursement controls, and competition from wound-care products that do not carry the same safety warning. Smith & Nephew has not reported standalone REGRANEX revenue, preventing a reliable product-level sales estimate. The product remains commercially relevant as a differentiated prescription therapy, but it is not a major growth asset within the broader advanced wound-care market.
What is REGRANEX and how does it work?
REGRANEX is a topical gel containing recombinant human platelet-derived growth factor-BB, or becaplermin. It is approved for the treatment of lower-extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. It is used with a program of good ulcer care, including initial sharp debridement, pressure relief, infection control, and management of blood glucose and vascular status. [1]
REGRANEX does not replace wound debridement, off-loading, vascular intervention, or infection management. Its commercial value depends on use in a highly controlled treatment pathway rather than broad prescription volume.
| Product attribute |
REGRANEX |
| Active ingredient |
Becaplermin |
| Concentration |
0.01% topical gel |
| Drug class |
Recombinant human platelet-derived growth factor-BB |
| Initial FDA approval |
1997 |
| FDA application |
NDA 020781 |
| Primary indication |
Diabetic neuropathic lower-extremity ulcers |
| Administration |
Topical, once daily |
| Key limitation |
Use is generally limited to a maximum of 20 weeks |
| Major safety issue |
Boxed warning concerning malignancy risk |
| Commercial owner |
Smith & Nephew-associated wound-care business |
| Product-level revenue disclosure |
Not separately reported |
When did REGRANEX lose commercial momentum?
REGRANEX lost momentum after postmarketing safety findings led to a boxed warning in 2008. FDA labeling reported an increased risk of mortality from all cancers in patients exposed to three or more tubes of REGRANEX. The warning did not establish that becaplermin caused cancer, but it materially changed prescribing behavior and restricted the product's risk-benefit profile. [2]
The label limits cumulative exposure and instructs clinicians to use the smallest quantity necessary to treat the ulcer. The recommended course is up to 20 weeks, with treatment discontinued if the ulcer does not show substantial healing after 10 weeks.
REGRANEX regulatory and commercial timeline
| Year |
Event |
Commercial effect |
| 1997 |
FDA approves REGRANEX for diabetic neuropathic ulcers |
Establishes a branded prescription market |
| 2000s |
Wider adoption in advanced wound care |
Supports premium pricing relative to standard dressings |
| 2008 |
FDA adds boxed warning concerning malignancy risk |
Reduces prescribing flexibility and increases payer scrutiny |
| 2010s |
Growth of cellular and tissue-based products, negative-pressure therapy, and advanced dressings |
Increases competitive pressure |
| 2010s-2020s |
Product revenue is absorbed into broader wound-care reporting |
Standalone financial performance becomes unavailable |
| Current commercial period |
Product remains a niche prescription option subject to safety and reimbursement controls |
Limited growth potential |
What is the FDA regulatory status of REGRANEX?
REGRANEX was approved through the FDA's new drug application pathway rather than as a biologic license application. Becaplermin is a recombinant protein, but its regulatory history is associated with NDA 020781. This distinction matters for follow-on competition: a potential competitor would generally assess the abbreviated new drug application pathway, product-specific FDA requirements, and any remaining listed patents or exclusivity.
The FDA-approved label includes a boxed warning for malignancies. REGRANEX is contraindicated in patients with known neoplasms at the site of application, and the label advises against use in patients with known malignancy. [1]
The product's regulatory risk is therefore different from that of a conventional topical small molecule. The active ingredient is a recombinant growth factor, and product quality depends on protein characterization, formulation, potency, container closure, and manufacturing controls.
What is the Orange Book status of REGRANEX?
REGRANEX's main regulatory protection is no longer its original FDA exclusivity. The product was approved in 1997, so the original five-year new chemical entity exclusivity and three-year clinical-investigation exclusivity periods have expired.
The commercial analysis now turns on three issues:
- Whether any patents remain listed in the FDA Orange Book.
- Whether a competitor can obtain an ANDA with an acceptable formulation and bioequivalence package.
- Whether manufacturing and clinical-risk requirements create a practical barrier even without strong patent protection.
Publicly available product information does not establish a material remaining period of branded regulatory exclusivity. Any current paragraph IV exposure would depend on the Orange Book listing at the time of an ANDA filing and the status of listed patents. [3]
What patents protect REGRANEX?
The original REGRANEX patent estate was directed primarily to recombinant platelet-derived growth factor, pharmaceutical compositions, and therapeutic use in wound healing. Patent protection associated with the original launch period would have expired or become commercially weak by the 2020s because the product was approved more than 25 years ago.
| Protection category |
Current commercial relevance |
| Recombinant PDGF-BB composition claims |
Likely expired or materially limited by age |
| Topical gel formulation claims |
Must be checked against current Orange Book listings |
| Diabetic-ulcer method claims |
Potentially relevant only if listed and enforceable |
| Manufacturing process claims |
May remain outside the Orange Book and create process-specific barriers |
| Trade secrets |
Potentially relevant to protein production, purification, potency testing, and formulation |
| FDA exclusivity |
Expired based on the 1997 approval date |
A competitor would not need to reproduce every manufacturing step used by the brand owner. It would need to demonstrate that its own process produces a consistent, clinically acceptable product. For a recombinant growth factor, that can create a larger practical barrier than the patent estate alone suggests.
Are generic or biosimilar competitors challenging REGRANEX?
No major public generic or biosimilar challenge is associated with REGRANEX in the available commercial record. The absence of a visible competitor does not prove that no ANDA has been filed. It indicates that no competitor has achieved market visibility comparable to the brand.
REGRANEX is not positioned like a typical injectable biologic with a large biosimilar market. Its topical route, low-volume diabetic-ulcer indication, historical safety warning, and uncertain reimbursement economics reduce the incentive for large manufacturers to invest in development.
Generic launch risks
A generic entrant would face several barriers:
- Demonstrating pharmaceutical equivalence for a recombinant protein gel.
- Establishing an FDA-acceptable bioequivalence strategy.
- Matching concentration, potency, delivery, and stability.
- Managing manufacturing costs at relatively low expected volume.
- Obtaining payer coverage in a market with competing wound-care modalities.
- Addressing the same malignancy warning carried by the reference product.
- Supporting physician adoption despite limited differentiation from the branded product.
The absence of patent-based exclusivity does not automatically create an attractive generic opportunity. The market must be large enough to support development, manufacturing, regulatory work, and payer contracting.
What formulations are protected by REGRANEX?
The commercial product is a low-concentration topical gel designed for direct application to the ulcer surface. The formulation must maintain becaplermin stability and biological activity during storage and use.
Formulation-related protection may arise from:
- Gel composition and excipients.
- Protein stabilization.
- Dose delivery and application volume.
- Container design and product handling.
- Shelf-life and storage conditions.
- Manufacturing controls that preserve biological potency.
The formulation is commercially important because the active ingredient is not a conventional chemically synthesized molecule. A competitor could face technical difficulty reproducing the product's performance even if broad composition patents are expired.
How does REGRANEX compare with competing diabetic-foot-ulcer treatments?
REGRANEX competes against products and procedures that often have different regulatory classifications and reimbursement pathways.
| Treatment category |
Typical commercial position versus REGRANEX |
| Standard moist wound care |
Lower-cost baseline treatment; used for nearly all ulcers |
| Off-loading devices |
Essential for pressure reduction; complementary rather than directly substitutive |
| Negative-pressure wound therapy |
Used for selected complex wounds; higher equipment and service costs |
| Cellular and tissue-based products |
Compete for advanced-wound-care spending; often used after standard care failure |
| Collagen and extracellular-matrix products |
Compete on wound-bed management and healing support |
| Hyperbaric oxygen therapy |
Used in selected ischemic or refractory wounds |
| Surgical and vascular interventions |
Address underlying structural or perfusion problems |
| REGRANEX |
Prescription growth-factor therapy with a boxed warning and defined treatment course |
REGRANEX has a more specific pharmacologic mechanism than dressings and matrix products. Its disadvantage is that it carries a safety warning and requires careful patient selection. In practice, prescribers and payers evaluate the drug within a broader wound-management algorithm rather than as a standalone therapy.
What financial trajectory has REGRANEX followed?
Smith & Nephew does not separately disclose REGRANEX revenue in its public financial statements. Revenue is reported within broader wound-management or advanced-wound-care categories. As a result, standalone sales, gross margin, operating profit, and product-level growth rates cannot be calculated from company filings.
The product's financial trajectory can be assessed directionally:
Launch and adoption phase
REGRANEX entered the market with an approved pharmacologic mechanism for diabetic ulcers and a premium prescription position. Its value proposition was strongest for patients whose ulcers had adequate perfusion and had not responded sufficiently to standard wound care.
Safety-constrained phase
The 2008 boxed warning reduced the product's addressable patient population and increased physician and payer caution. The cumulative-treatment limitation also capped revenue per treated patient. A therapy with a maximum treatment duration has less opportunity to generate recurring revenue than chronic-use products.
Competitive maturity phase
Advanced dressings, cellular products, negative-pressure systems, and improved diabetic-foot-care protocols expanded the competitive set. The product's growth became dependent on narrow clinical selection rather than market expansion.
Mature or declining phase
The lack of separately disclosed revenue suggests that REGRANEX is no longer financially material enough for Smith & Nephew to report as an independent product line. That does not establish discontinuation. It indicates that the product is economically embedded in a larger wound-care portfolio.
What revenue exposure does REGRANEX create for Smith & Nephew?
REGRANEX is unlikely to represent a material portion of Smith & Nephew's consolidated revenue. The company reports at the group and business-area level, and its major revenue drivers include orthopedic reconstruction, sports medicine, advanced wound management, and other medical technologies. [4]
The main financial exposures are:
- Product availability and manufacturing continuity.
- Reimbursement decisions by commercial insurers and government programs.
- Liability and pharmacovigilance costs associated with the boxed warning.
- Pricing pressure from wound-care substitutes.
- Potential erosion from an ANDA entrant.
- Declining use if clinicians favor cellular, matrix, or procedural alternatives.
Because treatment is finite, revenue is more closely linked to the number of eligible ulcers treated than to chronic patient retention. A larger diabetic population does not translate directly into proportional REGRANEX growth.
What licensing deals affect REGRANEX?
No major current licensing transaction is publicly associated with REGRANEX that would materially alter its market outlook. The product's commercial history involved ownership and portfolio changes within wound care, but current public reporting does not identify a separate royalty stream or an active licensing structure that drives product economics.
For transaction analysis, the relevant diligence points are:
- Ownership of the NDA and product trademarks.
- Rights to the becaplermin formulation and manufacturing process.
- Third-party supply agreements for recombinant protein.
- Pharmacovigilance obligations.
- Reimbursement and distribution contracts.
- Any territory-specific commercialization rights.
The commercial value of a transaction involving REGRANEX would depend more on manufacturing continuity and retained payer access than on long-dated patent exclusivity.
What patent litigation and settlement risks affect REGRANEX?
No major public paragraph IV litigation or generic settlement has shaped the REGRANEX market in the manner seen for high-revenue small-molecule medicines. The principal legal risks are more likely to involve product liability, promotional compliance, manufacturing quality, and patent disputes arising from a future follow-on product.
A generic entrant could still create litigation risk if it files a paragraph IV certification against an Orange Book-listed patent. The economic value of a settlement would be limited by the product's narrow market, boxed warning, and uncertain demand. A traditional "at-risk" launch would be less attractive unless the entrant had a low-cost manufacturing platform and strong payer access.
What generic launch scenarios exist for REGRANEX?
Scenario 1: No meaningful generic entry
This is the most commercially conservative scenario. The product remains available as a niche branded therapy, with revenue stable at a low level or gradually declining. Smith & Nephew continues to supply the market without investing heavily in expansion.
Scenario 2: One authorized or independent generic
A single competitor could capture price-sensitive prescriptions, particularly through Medicaid, managed-care formularies, and specialty pharmacy channels. The brand would likely retain some volume because of physician familiarity and limited clinical alternatives.
Scenario 3: Multiple generic entrants
Multiple entrants would create substantial price erosion. The market could contract if lower prices do not expand utilization enough to offset reduced revenue per tube. This outcome would be more likely if FDA requirements are manageable and a manufacturer already has recombinant-protein production capability.
Scenario 4: Discontinuation or market withdrawal
If manufacturing, pharmacovigilance, or distribution costs exceed product contribution, the commercial owner could reduce supply or withdraw the product. Such a decision would be a business action rather than evidence that FDA approval has been revoked.
How strong is the REGRANEX patent estate?
The REGRANEX patent estate is weak as a long-term exclusivity platform because the product was approved in 1997 and its principal commercial protection is mature. Its residual defensibility is more likely to come from manufacturing know-how, formulation performance, regulatory complexity, physician familiarity, and supply reliability.
| Estate component |
Assessment |
| Original composition protection |
Mature |
| Original FDA exclusivity |
Expired |
| Formulation protection |
Requires current Orange Book and patent-file review |
| Method-of-use protection |
Narrow and potentially vulnerable |
| Manufacturing know-how |
Potentially meaningful |
| Brand recognition |
Moderate among wound-care specialists |
| Regulatory barrier |
Moderate |
| Generic commercial threat |
Low to moderate, depending on FDA pathway and economics |
What is the geographic coverage of REGRANEX?
The United States is the principal reference market for assessing REGRANEX because the FDA label, Orange Book status, and U.S. reimbursement policies define the strongest public regulatory record. Commercial availability and patent protection may differ in Europe, Japan, Canada, and other markets.
Geographic value is constrained by:
- Local approval requirements for becaplermin.
- Different diabetic-foot-ulcer treatment guidelines.
- National reimbursement policies.
- Local pricing controls.
- Patent status by jurisdiction.
- Availability of alternative wound-care products.
- Local standards for recombinant-protein manufacturing.
The U.S. product cannot be assumed to have identical exclusivity, labeling, or market access in other jurisdictions.
Key Takeaways
- REGRANEX is a topical becaplermin product approved by FDA in 1997 for diabetic neuropathic lower-extremity ulcers.
- Its commercial position weakened after the 2008 boxed warning concerning malignancy risk.
- The product has a finite treatment course, which limits recurring revenue per patient.
- Smith & Nephew does not report standalone REGRANEX revenue.
- Current financial exposure is likely small relative to Smith & Nephew's consolidated and wound-care portfolios.
- Original regulatory exclusivity has expired.
- Patent value is likely concentrated in any remaining formulation or method claims and in manufacturing know-how.
- No major public paragraph IV challenge or biosimilar campaign is associated with REGRANEX.
- Generic entry is technically possible but commercially constrained by low market scale, recombinant-protein manufacturing, safety labeling, and payer economics.
- The product's strongest defenses are regulatory complexity, established supply, physician familiarity, and manufacturing capability rather than long-lived patent exclusivity.
FAQs
Is REGRANEX still FDA approved?
REGRANEX was approved under NDA 020781 in 1997. FDA approval history and current commercial availability are separate questions; approval does not guarantee continuous commercial supply.
Is becaplermin a biologic or a generic drug?
Becaplermin is a recombinant protein, but REGRANEX was approved through an NDA rather than a biologics license application. A follow-on product would need to satisfy the FDA pathway and product-specific requirements applicable to the reference drug.
Does REGRANEX have a biosimilar?
No major FDA-recognized biosimilar market has developed for REGRANEX. A competitor would more likely evaluate an abbreviated drug-approval strategy than the standard injectable-biosimilar model.
Why is REGRANEX used for only a limited period?
The FDA label limits treatment duration and cumulative exposure because of the product's safety profile and the absence of demonstrated benefit from prolonged use. Treatment is discontinued when healing progress is inadequate.
What is the main investment risk associated with REGRANEX?
The main risk is declining commercial relevance without a compensating growth market. Revenue is exposed to the boxed warning, finite treatment duration, alternative wound-care technologies, payer restrictions, and potential future generic competition.
References
- U.S. Food and Drug Administration. (n.d.). REGRANEX (becaplermin) gel prescribing information.
- U.S. Food and Drug Administration. (2008). FDA public health advisory: Regranex (becaplermin) gel and cancer risk.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Smith & Nephew plc. (2024). Annual report and accounts 2023.
